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Abstract.  Tenofovir  is  widely  used  as  first
sometimes complicated by a reversible proximal renal tubulopathy. 
We report the case of a 45-year-old woman with chronic HIV infection and personality disorder, 
who after 12 months of tenofovir, complained of fatigue, diffuse bone pain and gait disturbances. 
The  elevated  level  of  alkaline  phosphatase,  hypophosphatemia  an
suggested  the  diagnosis  of  hypophosphatemic  osteomalacia  secondary  to  proximal  renal 
tubulopathy. A  dual-energy  x-ray  absorptiometry  showed  a  bone  mineral  density  below  the 
expected range for age (lumbar spine Z
methylene diphosphonate bone scan showed multiple areas of increased focal activity in the 
and thoracic spine and in sacroiliac and hip joints 
after  tenofovir  discontinuation  and  administration  of  vitamin  D  and  phosphate,  osteomalacia
related  symptoms  disappeared.  Eleven  months  later,  bone  and  mineral  metabolism  data  were 
normal and bone scintigraphy did not show any pathological findings. 
This  report  highlights the  importance  of  considering  the  diagnosis  of  osteomalacia  in  patients 
treated with tenofovir and emphasizes the need for monitoring alkaline phosphatase, blood and 
urinary phosphate and creatinine, especially in patients with risk factors for bone disea
Introduction. A number of  bone diseases, including 
osteoporosis,
1 osteonecrosis
2 and  even  osteomalacia 
(OM), although rare,
3,4 have been described in 
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Tenofovir  is  widely  used  as  first-line  treatment  of  HIV  infection,  although  its  use  is 
sometimes complicated by a reversible proximal renal tubulopathy. 
old woman with chronic HIV infection and personality disorder, 
who after 12 months of tenofovir, complained of fatigue, diffuse bone pain and gait disturbances. 
The  elevated  level  of  alkaline  phosphatase,  hypophosphatemia  and  inappropriate  phosphaturia 
suggested  the  diagnosis  of  hypophosphatemic  osteomalacia  secondary  to  proximal  renal 
ray  absorptiometry  showed  a  bone  mineral  density  below  the 
expected range for age (lumbar spine Z-score -3.3, femoral neck Z-score -2.1).
methylene diphosphonate bone scan showed multiple areas of increased focal activity in the 
and thoracic spine and in sacroiliac and hip joints consistent with pseudo-
iscontinuation  and  administration  of  vitamin  D  and  phosphate,  osteomalacia
related  symptoms  disappeared.  Eleven  months  later,  bone  and  mineral  metabolism  data  were 
normal and bone scintigraphy did not show any pathological findings. 
the  importance  of  considering  the  diagnosis  of  osteomalacia  in  patients 
treated with tenofovir and emphasizes the need for monitoring alkaline phosphatase, blood and 
urinary phosphate and creatinine, especially in patients with risk factors for bone disea
A number of  bone diseases, including 
and  even  osteomalacia 
have been described in human 
immunodeficiency  virus  (HIV)
considered due to HIV infection itself, to HIV
co-morbiditiers as well as to drug toxicity. Tenofovir 
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old woman with chronic HIV infection and personality disorder, 
who after 12 months of tenofovir, complained of fatigue, diffuse bone pain and gait disturbances. 
d  inappropriate  phosphaturia 
suggested  the  diagnosis  of  hypophosphatemic  osteomalacia  secondary  to  proximal  renal 
ray  absorptiometry  showed  a  bone  mineral  density  below  the 
2.1). A whole body 
99mTc-
methylene diphosphonate bone scan showed multiple areas of increased focal activity in the lumbar 
-fractures. Two months 
iscontinuation  and  administration  of  vitamin  D  and  phosphate,  osteomalacia-
related  symptoms  disappeared.  Eleven  months  later,  bone  and  mineral  metabolism  data  were 
the  importance  of  considering  the  diagnosis  of  osteomalacia  in  patients 
treated with tenofovir and emphasizes the need for monitoring alkaline phosphatase, blood and 
urinary phosphate and creatinine, especially in patients with risk factors for bone disease.
HIV)-positive  patients,  and 
considered due to HIV infection itself, to HIV-related 
morbiditiers as well as to drug toxicity. Tenofovir Mediterr J Hematol Infect Dis 2012; 4: Open Journal System
disoproxil fumarate (TDF) (Viread 
®) is the oral pro-
drug of TDF, an adenine analog reverse transcriptase 
inhibitor,  widely  prescribed  in  combination  with 
antiretroviral  therapy  (ART),  because  of  convenient 
dosage  and  a  good  safety profile.  However, there  is 
concern about its potential nephrotoxicity. TDF use, in 
fact,  has  been  associated  with  proximal  renal 
tubulopathy  (PRT)  and  loss  in  bone  mineral  density 
(BMD).
5,6 Minor proximal renal tubule abnormalities 
leading  to  phosphate  wasting  and  1-α-hydroxylation 
defects  of  vitamin  D  with  subsequent  clinical  OM, 
have  been  found  in  1.6%  to  22%  of  TDF-treated 
patients.
7,8
TDF  toxicity  may  be  increased  in  HIV-infected 
subjects because of their accelerated biological aging ,
9
difficult to  treat  co-morbidities,  including psychiatric 
disorders
10,11 and complex drug regimens.
12 The case of 
TDF-induced  OM  in  a  patient  with  chronic  HIV 
infection here reported might  provide an opportunity 
for  an  important  “teaching  point”  In  prospective 
controlled clinical trials, in fact, a specific, “ad hoc” 
investigation of  bone TDF toxicity is lacking, and the 
only  available  informations  are  coming  from  case 
reports and observational case series. 
Case  Report.  A  45-year-old  HIV-infected  woman 
came to  our  observation in  March  2010  with a  4-6-
month history of fatigue, severe pain in the hip joints, 
rib  cage,  dorsal  and  lumbosacral  spine,  causing  gait 
instability. She after 12 months of ART including TDF, 
complained  initial  gait  disturbances.  Her  HIV-1 
infection  was  probably  due  to  unprotected  sexual 
contacts  prior  to  1988.  She  also  had  chronic  HCV-
related    hepatitis  (genotype  1b)  and  borderline 
personality  disorder.  Her  family  history  was 
unremarkable. In the past, she had been treated with 
several  antiretroviral  therapies,  although  not  strictly 
followed  because  of  her  psychiatric  disorder.  Since 
September  2008,  once admitted  in  a  non-profit 
Residential  Care  Facility, she  was  receiving  regular 
ART.  At  the  last  follow-up, HIV-1  RNA  count  was
almost undetectable levels (<20 copies/mL) and CD4
cell  count  was  322/mm
3,  while  in  September  2008
HIV-1  RNA  was  510  copies/mL and  the  CD4  cell
Figure 1. Whole body 
99mTc-MDP bone scintigraphy. Panel A (anterior and posterior), at clinical presentation: increased focal uptake in the 
lumbar/thoracic spine, sacroiliac regions and hip joints consistent with multiple pseudofractures. Panel B (anterior and posterior), eight 
months after TDF discontinuation: absence of increased uptake.Mediterr J Hematol Infect Dis 2012; 4: Open Journal System
Figure 2. Dorso-lumbosacral spine X-ray: fracture deformities of D/7and of the bodies of L/2-4, in a general aspect of diffuse osteopenia.
count  298/mm
3.  When  first  visited  by us  (on March 
2010),    her  treatment  included  zidovudine  300  mg 
every 12h,    TDF 245  mg daily, atazanavir 300 mg 
daily boosted by ritonavir 100 mg daily, risperidone 3 
mg b.i.d., levopromazine 100 mg t. i. d., valproate 500 
mg b.i.d, clonazepam 5 mg t.i.d. Her weight was 65 
Kg, height 153 cm, body mass index (BMI) 27 Kg/m
2, 
she  had  proximal  muscle  weakness,  diffuse  bone 
tenderness and antalgic gait. 
Laboratory values at presentation and during follow 
up  are  summarized  in  table  1.  A  DXA  scan  was 
performed in March 2010 and showed a BMD of 0.459
g/cm
2 (Z-score -3.3) at the L2-L4 level of the spine and 
of 0.549 g/cm
2 (Z-score -2.1) at the femoral neck. The 
whole  body 
99mTc-methylene  diphosphonate  (
99mTc-
MDP) bone scintigraphy showed an increased uptake 
at the lumbar and thoracic spine, sacroiliac region and 
hip  joints,  consistent  with  multiple  pseudo-fractures 
(figure 1, panel A). The dorsal and lumbosacral spine 
X-ray showed diffuse osteopenia, fracture deformities 
of D7and L2-L4 (Figure 2). Because of the temporal 
relationship between the beginning of TDF therapy and 
OM-related  symptoms,  in  the  absence  of  other 
explanations and in accord  with previously published 
similar  cases,
4,13 we  made  a  diagnosis  of 
hypophosphatemic  TDF-induced  OM.  TDF  was 
stopped and the ART modified to darunavir boosted by 
ritonavir,  emitricitabine  and  raltegravir.  In  addition, 
oral cholecalciferol (300,000 IU/daily for 2 days and 
10,000  IU/week),  calcitriol  (0.25  mcg  /daily)  and 
neutral  sodium-potassium  phosphate  containing  1500 
mg of phosphorus/daily were given. Two months after 
discontinuation  of  TDF,  bone  pain  and  gait 
disturbances  as  well  as  laboratory  data  were 
significantly improved (Table 1). Eleven months later, 
the patient was free of bone and joint-related symptoms 
and  a  whole  body 
99mTc-MDP  bone  scintigraphy 
showed  complete  resolution  of  the  OM  (Figure  1, 
Panel B). 
Discussion. In the last 10 years, the life expectancy of 
adults  with  HIV  infection has  increased; the  care  of 
HIV-infected  individuals  has  evolved  from 
management of opportunistic infections to prevention 
and treatment of the metabolic complications of ART, 
including osteoporosis. HIV and/or ART-related bone 
damage  coupled  with  the  bone  loss  characteristic  of 
older age could lead to a serious health threat. Bone 
loss,  in  fact,  has  been  reported  to  be  an  accelerated 
event during ART, especially within the first 6 months 
of therapy.
14 The SMART (Strategies for Management 
of Antiretroviral Therapy) Study has shown that ART 
may be associated with a 6% decrease in BMD during 
the  first  2  years  regardless  of  the  drug  combination 
used.
14 Therefore, osteopenia, osteoporosis, and even, 
albeit rarely, osteomalacia, with a consequent increased 
risk  of  fracture  are  major  adverse  effects  of  ART, 
especially in  a regimen including TDF.
15 TDF  dose-
dependent kidney toxicity, generally occurring within  
the first 4-12 months, is well known. In a recent meta-
analysis,
16 a  significant  loss  of    3.92  mL/min  of 
estimated  glomerular  filtration  rate  (eGFR)  has  beenMediterr J Hematol Infect Dis 2012; 4: Open Journal System
Table 1. Laboratory investigations at presentation and during follow-up.
Laboratory tests At presentation 
(during TDF 
therapy)
Two months after the 
TDF discontinuation
Eleven months 
after the TDF 
discontinuation
Normal range
Phosphate (mg/dL) 1.5 4.2 3.5 2.5- 5.0
Calcium (mg/dL) 8.9 9.6 9.6 8.5- 10.7
Alkaline phosphatase (IU/L) 1356 678 191 80-320
γ –glutamyltranspeptidase (UI/L) 235 162 159 7- 49
25-OH vitamin D (ng/mL) 5 39 optimal concentration: 
>30 ng/mL
Parathyroid Hormone (ng/L) 47 12-72
Creatinine (mg/dL) 0.99 0.92 0.87 0.5-1.4
eGFR* (mL/min/1.73 m) 64 70 75
Urinary calcium  (mg/24h) 102 100-300
Urinary phosphorus (g/24h) 0.38 0.3-1.0
*estimated Glomerular Filtration Rate (eGFR) using the Modification of Diet in Renal Disease study group formula (MDRD)
reported with TDF use. Although mild, such reduction 
might  become  important  in  patients  with  prior 
underlying  renal  diseases,  with  potential  nephrotoxic 
medications or comorbidities. Moreover, renal toxicity 
could  be  underestimated  if  evaluated  as  GFR  alone 
rather  than PRT  toxicity.  The  PRT  may  result  in 
phosphate wasting only or may progress to complete 
proximal  tubular  damage  (De  Toni-Debré-Fanconi 
syndrome),  with  impaired  reabsorption  and  urine 
wasting of phosphate, calcium, magnesium, potassium, 
sodium, urate, amino acids, glucose and bicarbonate, 
resulting  in  hypophosphatemic  OM  and  metabolic 
acidosis.    Although  the  relative risk of  grade 3-4 of 
hypophosphatemia has been reported to be low,
16 TDF 
dose adjustments are required in chronic renal diseases 
with  eGFR  lower  than  50  mL/min,  to  avoid  TDF 
accumulation  and  further  renal  injury.  The  proximal 
tubule is most commonly affected because it is a major 
site  for  the  excretion  of  xenobiotics.  However,  the 
mechanism  of  TDF  nephrotoxicity  is  not  well 
understood.  Mitochondrial  damage  and  alterations  in 
human  organic  anion  transporter  1  have  been 
suggested.
20 Proximal tubule mitochondrial injury, in 
part due to decreasing mitochondrial DNA replication 
through inhibition of mitochondrial DNA polymerase, 
would  impair  molecular  transport,  vitamin  D 
activation, and urinary acidification.
8 An increased risk 
of  renal  damage  has  been  reported  with  TDF  given 
with  ritonavir-boosted  protease  inhibitors.
18,19
Specifically,  co-administration  of  TDF  with 
atazanavir/ritonavir resulted in increases of TDF serum 
concentrations. Thus, patients who were receiving both 
ritonavir and atazanavir should be carefully monitored 
for  an  increase  in  TDF-associated  adverse  effects.
20
Other  factors  that  may  increase  TDF  nephrotoxicity 
include  a  low  BMI  and  the  concomitant  use  of 
nonsteroidal  antiinflammatory  drugs.  The  rapid 
withdrawal  of  the  drug  usually  reverses  the  renal 
damage,  but  a  permanent  De  Toni-Debré-Fanconi 
syndrome  may ensue.  The  link  between  kidney  and 
bone  toxicity  of  TDF  is  obvious,  since 
hypophosphatemia  may  cause  an  inadequate 
mineralization  of  the  bone  matrix,  with  subsequent 
rickets or OM. 
In  the  patient  reported  here  the  symptoms,  the 
laboratory  abnormalities (increased  ALP  activity, 
phosphate  wasting  with  persistently  low  serum 
phosphate) and the imaging data (multiple ribs pseudo-
fractures  and  vertebral  fractures)  led  us  to  diagnose 
hypophosphatemic  OM  due  to  TDF  toxicity,  even 
without bone histomorphometry. The hypovitaminosis 
D could have partially contributed to OM. The normal 
PTH level which may seem peculiar in the presence of 
vitamin D deficiency, might be related to a negative 
feedback  of  hypophosphatemia  on  the  parathyroid 
glands,  being  phosphate  an  important  regulator  of 
PTH.
21 The  normal  level  of  PTH,  in  the  setting  of 
hypovitaminosis D, associated with hypophosphatemia 
was consistent with hypophosphatemia as the prevalent 
metabolic  alteration  in  our  patient.  The  dramatic 
clinical  and  laboratory  improvements  observed  with 
the discontinuation of the drug confirmed the diagnosis 
of OM. The presence of liver and psychiatric disorders 
and  the  complex  drug  regimens  could  have 
significantly  contributed  to  the  increased  risk  of 
fractures  since  a  low  BMD  has  been  linked  to 
borderline  personality  disorders.
22 Of  particular 
concern  from  a  clinical  point  of  view  is  that 
pseudofractures  in  OM  can  be  misdiagnosed  as 
disseminated  bone  malignancy,  because  the  whole 
body scintigraphy, in the late stage of OM, such in our 
case, shows a bone pattern of diffuse or focal tracer’s 
uptake,  that  is  similar  to  bone  metastases.  In 
conclusion,  adverse  effects,  virtually  found  with  all 
antiretroviral  drugs,  are  the  major  cause  for  the 
switching  or  discontinuation  of  the  therapy  and for 
poor medication adherence. Although bone damage is 
common in HIV patients, alternative causes, including 
drug toxicity, must be searched because often can be 
easily treated. In particular, clinicians should be aware 
of  TDF  induced-OM,  especially  in  patients  with 
relevant  co-morbidities  and  complex  therapy.  In Mediterr J Hematol Infect Dis 2012; 4: Open Journal System
patients  treated  with  TDF,  a  monitoring  of  serum 
phosphorus,  creatinine and  ALP  could  be  performed 
according  to  the  European  AIDS  Clinical  Society 
(EACS) guidelines,
23 and a pre-treatment dosage and 
implementation  of vitamin  D,  may  be  convenient. If
hypophosphatemic  OM  is  suspected,  a  rapid 
discontinuation  of  the  medication  is  necessary  to 
prevent  a  permanent  renal  damage,  moreover 
phosphate, calcitriol and cholecalciferol administration 
seems  to  be  useful  to  accelerate  recovery  from  the 
disease. 
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